Gene:
SCG2
secretogranin II

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  chromogranin C; secretoneurin
Alternate Symbols:  CHGC; SN; SgII
PharmGKB Accession Id: PA34987

Details

Cytogenetic Location: chr2 : q35 - q36.1
GP mRNA Boundary: chr2 : 224461658 - 224467217
GP Gene Boundary: chr2 : 224458658 - 224477217
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
antipsychotics

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Schizophrenia

Publications related to SCG2: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. American journal of human genetics. 2008. Mill Jonathan, et al. PubMed

LinkOuts

NCBI Gene:
7857
OMIM:
118930
UCSC Genome Browser:
NM_003469
RefSeq RNA:
NM_003469
RefSeq Protein:
NP_003460
RefSeq DNA:
NT_005403
UniProtKB:
SCG2_HUMAN (P13521)
Ensembl:
ENSG00000171951
GenAtlas:
SCG2
GeneCard:
SCG2
MutDB:
SCG2
ALFRED:
LO021386U
HuGE:
SCG2
Comparative Toxicogenomics Database:
7857
ModBase:
P13521
HumanCyc Gene:
HS10421
HGNC:
10575

Common Searches